KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) EBT Margin (2016 - 2025)

Pfizer (PFE) has disclosed EBT Margin for 17 consecutive years, with 5.15% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin fell 517.0% to 5.15% in Q4 2025 year-over-year; TTM through Dec 2025 was 21.21%, a 6115.0% increase, with the full-year FY2025 number at 12.02%, down 8363.0% from a year prior.
  • EBT Margin was 5.15% for Q4 2025 at Pfizer, down from 395.47% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 1066.74% in Q3 2024 to a low of 120.24% in Q4 2023.
  • A 5-year average of 104.79% and a median of 36.02% in 2021 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: soared 109159bps in 2024, then plummeted -67127bps in 2025.
  • Pfizer's EBT Margin stood at 85.02% in 2021, then tumbled by -53bps to 39.76% in 2022, then plummeted by -402bps to 120.24% in 2023, then surged by 100bps to 0.03% in 2024, then tumbled by -19382bps to 5.15% in 2025.
  • Per Business Quant, the three most recent readings for PFE's EBT Margin are 5.15% (Q4 2025), 395.47% (Q3 2025), and 20.78% (Q2 2025).